SA
SNPHY logo
Santen Pharmaceutical Co., Ltd.(SNPHY)
Closing price · checked 11:13 PM ETAbout this dataData status
$12.50▼-0.06 (-0.48%)
Extended:$12.50+0.00 (+0.00%)· 11:13 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Santen Pharmaceutical Co., Ltd. (SNPHY)

Net Acquisitions

¥0.00

TTM · Period ending: · JPY

SNPHY logo

SNPHY Net Acquisitions

Latest reported¥0.00 JPY
SNPHY Net Acquisitions · JPY (¥2.49B → ¥0.00)
High-resolution chart · PNG

What is net acquisitions?

Cash spent on business acquisitions (net).

SNPHY net acquisitions history

Annual fiscal periods · JPY. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Santen Pharmaceutical Co., Ltd. Net Acquisitions — Annual fiscal periods (JPY)
Period endingNet Acquisitions (JPY)Change
0—
0—
-207,000,000—
-3,470,000,000—
-2,969,000,000—
-29,183,000,000—
-3,404,000,000−330.78%
1,475,000,000—
-5,953,000,000—
-19,064,000,000—
-4,097,000,000—
-62,812,000,000—
0—
0—
-10,804,000,000—
0—
0—
0—
0—
0−100.00%
29,000,000−98.83%
2,488,000,000—

Frequently asked questions: SNPHY net acquisitions

What is Santen Pharmaceutical Co., Ltd. (SNPHY)'s current net acquisitions?

Santen Pharmaceutical Co., Ltd. (SNPHY)'s latest reported net acquisitions (TTM) is ¥0.00 as of Sep 30, 2026. Cash spent on business acquisitions (net).

How much historical net acquisitions data is available for SNPHY?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for Santen Pharmaceutical Co., Ltd. (SNPHY)'s net acquisitions, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SNPHY's net acquisitions to peers or set an alert?

You can open SNPHY's net acquisitions in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SNPHY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.